The previous studies showed that clinical use of proinflammatory markers (TLR2, TLR2, TLR4, TNF-α, sTNFR-1, and sTNFR-2) provided a means of evaluating inflammatory diseases such as inflammatory bowel disease, breast cancer, coronary artery disease, chronic heart failure, and type 2 diabetes. This evidence concerns the gene TNF and inflammatory bowel disease.